Astellas Pharma Inc 2005 SR
The report outlines the CSR initiatives of the newly formed Astellas Pharma Inc. following the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical in April 2005. It covers environmental, safety, and compliance activities for the fiscal year 2004, providing aggregated data from the predecessor companies. Key highlights include the establishment of a CSR committee, the introduction of the 'Astellas C-file' code of conduct, and progress toward CO2 reduction and waste recycling targets. The company also details its response to a significant industrial accident at its Osaka Plant and its commitment to 'green' chemistry and ethical R&D.
Company: Astellas Pharma Inc
Sector: Health Care
Country: Japan
Year: 2005
Type: SR
Pages: 55
Astellas Pharma Inc
CSR Report
The report outlines the CSR initiatives of the newly formed Astellas Pharma Inc. following the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical in April 2005. It covers environmental, safety, and compliance activities for the fiscal year 2004, providing aggregated data from the predecessor companies. Key highlights include the establishment of a CSR committee, the introduction of the 'Astellas C-file' code of conduct, and progress toward CO2 reduction and waste recycling targets. The company also details its response to a significant industrial accident at its Osaka Plant and its commitment to 'green' chemistry and ethical R&D.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2005
Reporting Period
Apr 1, 2004 - Mar 31, 2005
Fiscal Year
2004
Published
Sep 1, 2005
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees